Pharma Does Not Need a New AI Governance Religion
It needs to extend the quality system it already uses. A QikSolve perspective on mapping AI agent management maturity to QMS maturity.
GMP & Quality Leadership
April 2026
The Governance Foundation Already Exists
Most industries are still working out how to implement and govern AI. Pharma is in a different position.
In GMP environments, governance is already an operating discipline. The Pharmaceutical Quality System (PQS), supported by Quality by Design (QbD), Critical to Quality (CTQ), and process parameter control, already provides a practical foundation for governing a new type of worker: the AI agent.
The opportunity is not to invent a parallel governance stack. It is to map AI agent management maturity to quality management maturity — and run it with the same rigour already applied to every other regulated process.
"AI governance in pharma is not a greenfield problem. It is a quality-systems extension problem."
Why This Matters Now
Agentic AI Is Arriving — and Pharma Already Speaks the Language
Recent Agentic DevOps direction from Microsoft emphasises stronger lifecycle controls, trust boundaries, layered verification, and continuous evaluation for AI agents. For pharma teams, this is not unfamiliar territory. It maps closely to existing GMP operating logic — language that quality leaders have applied for decades.
Define Up Front
Establish intended use and quality objectives before deployment, not after problems arise.
Control the Process
Manage the conditions that materially influence quality outcomes throughout execution.
Verify Continuously
Monitor agent performance against defined CTQs throughout the operational lifecycle.
Act on Drift
Trigger corrective action when performance deviates from approved operating ranges.
This is already how mature quality systems are managed. The vocabulary of AI agent governance and GMP governance are, in practice, the same.
AI Governance Is a Systems Problem — Not a Model Problem
When an AI agent participates in a regulated workflow, governance cannot rely on isolated model checks alone. The full operating system must be brought under control. Treating agent governance as a purely technical or IT concern misses the point entirely.
Role & Intended Use
Clearly defined function within the regulated workflow, with documented decision boundaries and scope limitations.
Approved Data & Tool Boundaries
Explicit allow-lists for data sources, retrieval scope, and tool permissions — controlled, not assumed.
Execution Controls
Runtime configuration, model version, prompt version, and fallback routing treated as controlled parameters.
Human Review Points
Mandatory review gates at compliance-critical decision points, with evidence of review captured.
Evidence & Traceability
Audit-ready provenance records for all agent outputs used in regulated decisions.
Change Control & Revalidation
Formal lifecycle gates for model updates, prompt changes, and configuration modifications.
That is a systems view — and it aligns directly with PQS principles already embedded in mature pharmaceutical organisations.
The Five-Level Maturity Map: AI Agents to QMS
AI agent management maturity can be mapped directly to QMS maturity levels. Each level carries a corresponding QbD, CTQ, and CPP interpretation — and a characteristic governance signal observable in practice.
Applying QbD to AI Agents
Quality by Design principles translate directly to agent deployment. Before any AI agent enters a regulated workflow, teams should define an Agent Quality Target Profile — the agent equivalent of a product quality target profile used in pharmaceutical development.
01
Intended Role
Define the agent's specific function within the process and the decisions it is — and is not — authorised to make.
02
Decision Boundaries
Document the scope of permissible actions, escalation triggers, and hard-stop conditions.
03
Required Evidence Outputs
Specify what traceability records the agent must generate for each regulated decision or action.
04
Acceptable Failure Modes
Define anticipated failure conditions and pre-approved fallback behaviours for each scenario.
05
Human Checkpoints
Identify mandatory human review gates required before the agent's output may be used in a compliance-critical step.
CTQ and CPP-Style Controls for AI Agents
Critical to Quality (CTQ) Attributes
Define what is non-negotiable in the regulated context. These are the measurable outputs that determine whether the agent is performing within acceptable quality limits.
Output accuracy against approved references
Provenance completeness of retrieved information
Explainability at the required review depth
Review-gate compliance at all defined checkpoints
Timeliness within approved process windows
Critical Process Parameters (CPP-Style Controls)
Identify the operating parameters that materially influence CTQ outcomes. These must be treated as controlled parameters — documented, baselined, and subject to change control.
Model version and runtime configuration
Instruction and prompt version
Retrieval scope and source allow-list
Tool permissions and action boundaries
Confidence thresholds and fallback routing
Timeout and retry policy settings
Treating these parameters as informal settings — rather than controlled inputs — is where AI agent governance breaks down in regulated environments.
A Practical Rollout Pattern for GMP Teams
Teams do not need to reach Level 5 maturity before deploying AI agents responsibly. A structured, stage-gated rollout pattern allows capability to scale while preserving audit readiness and process integrity at every step.
This pattern mirrors the phased approach used in process validation and CAPA management — familiar disciplines for any GMP quality team. Starting at Step 1 and progressing through each gate ensures that AI agent deployment does not outpace the governance infrastructure supporting it.
Where QikSolve Fits
QikSolve's perspective is that regulated organisations do not need to choose between AI adoption and governance discipline. These are not competing priorities — they are, when approached correctly, mutually reinforcing.
AI-assisted operations are designed to support compliance outcomes when implemented with clear boundaries, traceability, and human oversight built in from the start. In practice, this means extending existing quality governance patterns to AI agents rather than bypassing them.
The organisations that will scale AI capability most sustainably in GMP environments are those that treat agent governance as a quality systems question — not an IT question, not a legal question, and not a problem to solve after deployment.
"The fastest path to safe AI adoption in GMP is to govern agents with the same discipline used for any critical process."
The Foundation Is Already There
The key insight for pharma quality leaders is straightforward: the bedrock for AI agent governance already exists inside mature quality systems. The work is structured adaptation — not reinvention.
Map
Align agent maturity levels to your QMS maturity — identify where you are today and where governance gaps exist.
Apply
Use QbD, CTQ, and CPP frameworks to define, control, and measure AI agent performance as regulated processes.
Verify
Monitor continuously against defined quality attributes — detect drift before it becomes a compliance event.
Improve
Feed performance findings into CAPA-style cycles for systematic, documented improvement over time.
"Pharma already has the governance bedrock. The work now is structured adaptation, not reinvention."
A QikSolve perspective — April 2026